Navigation Links
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
Date:11/24/2009

SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the appointment of John A. Orwin to its Board of Directors, effective November 19, 2009. Mr. Orwin is a 20-year sales and marketing veteran in the biopharmaceutical industry and has been instrumental in the launch of several important therapeutics.

Mr. Orwin currently serves as Senior Vice President, BioOncology Business Unit at Genentech, Inc., a wholly-owned member of the Roche Group. In this role he is responsible for marketing, sales, business unit and late stage pipeline brand management for the largest oncology portfolio in the United States. Mr. Orwin led the successful introduction of several indications for the blockbuster products Avastin®, Rituxan®, Herceptin®, and Tarceva® in the United States. He has also served as a member of the several governance committees between Genentech and Roche, Biogen Idec, and OSI Pharmaceuticals.

From 2001 to 2004, Mr. Orwin achieved increasing responsibility at Johnson & Johnson, up to Franchise Vice President, Oncology Franchise at Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P. His previous experience includes the positions of Senior Director, Oncology Marketing at Alza Pharmaceuticals (acquired by Johnson & Johnson); Vice President, Marketing at Sangstat Medical Corporation; Marketing Director, Asthma at Rhone-Poulenc Rorer Pharmaceuticals; and Product Manager, Schering Oncology/Biotech at Schering-Plough Corporation. He led the successful launch of Taxotere in the United States while at Rhone-Poulenc Rorer and Thymoglobulin for Sangstat Medical Corporation.

Jean-Jacques Bienaime, Chairman of the NeurogesX Bo
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
2. NeurogesX Expands Commercial Operations Leadership Team
3. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
4. NeurogesX to Present at JMP Securities Healthcare Focus Conference
5. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
6. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
9. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
10. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
(Date:7/24/2014)... July 24, 2014  Perrigo Company (NYSE: ... an AB therapeutic equivalent rating from the U.S. Food ... Drug Application (NDA) for testosterone gel 1.0%. FDA concluded ... AndroGel 1% and can be substituted with the full ... and safety profile as AndroGel 1% when used under ...
(Date:7/24/2014)... N.Y. , July 24, 2014  Kinex Pharmaceuticals ... FDA for the Company,s KX2-391 Ointment for the commencement ... This is the Company,s third IND to be allowed ... KX2-391 is a synthetic, orally active and ... tubulin polymerization. KX2-391 promotes the induction of p53, G2/M ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... budget pressures, countries around the world are making ... lure the biopharmaceutical research sector away from the ... Technology Partnership Practice. The study, commissioned ... (PhRMA), further found that while many countries are ...
...   Accuray Incorporated (Nasdaq: ARAY ), ... of Richard Pettingill, LFACHE as a member of the ... Richard Pettingill,s career as a healthcare executive ... variety of prominent organizations. Most recently, Pettingill, who is ...
Cached Medicine Technology:New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 2New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 3Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 2Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 3
(Date:7/24/2014)... New York (PRWEB) July 24, 2014 ... lawsuit ( http://www.drugbot.com/testosterone/lawsuit/ ) against the manufacturer of ... the risks associated with the low testosterone injection, ... which was filed in the Ontario Superior Court ... that use of low testosterone therapy is associated ...
(Date:7/24/2014)... 2014) -- Some babies are at risk for autism because ... To find new ways to detect Autism Spectrum Disorder (ASD) ... interactions with others and how they relate to the possibility ... us to understand the connection between early joint attention before ... early form of communication that develops toward the end of ...
(Date:7/24/2014)... Philadelphia, PA (PRWEB) July 24, 2014 ... boutique, has announced that it will operate globally under ... The firm remains a woman-owned Employee Stock Ownership Plan ... Susan Schwartz McDonald, Ph.D . The firm ... techniques and powerful analytics. , Said McDonald, “We ...
(Date:7/24/2014)... 5 percent of all prenatal ultrasounds uncover antenatal ... prenatal abnormality in the United States. Many children ... antibiotics for the first few years of life ... urinary tract infections. Until recently, however, little evidence ... which involves considerable cost and inconvenience for families. ...
(Date:7/24/2014)... North American air and missile defense radar market is estimated ... register a CAGR of 8.22% to reach $2.7 billion in ... air and missile defense radar system. However, in the recent ... well. , Browse through the TOC of the North American ... idea of the in-depth analysis provided. This report also provides ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 3Health News:Early warning sign for babies at risk of autism 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Continuous antibiotics not necessary for many children with common prenatal abnormality 2Health News:Continuous antibiotics not necessary for many children with common prenatal abnormality 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4
... By Amanda Gardner HealthDay Reporter , SATURDAY, ... millions is now showing promise against a variety of different ... Saturday at the annual meeting of the American Association for ... the brand name Glucophage, among others), appeared linked to a ...
... Mann HealthDay Reporter , FRIDAY, March 30 (HealthDay ... it will require the tobacco industry to report on a ... any claims for "safer" tobacco products. Both actions are ... public comment. While there are more than 7,000 ...
... CHICAGO The use of metformin in men with prostate ... slow the growth rate of the cancer, according to the ... Joshua, M.B.B.S., Ph.D., staff medical oncologist at the Princess Margaret ... data at the AACR Annual Meeting 2012, held here March ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, ... about two hours more in labor during childbirth than women ... report,s authors said several factors helped to explain the longer ... a ratio of weight to height) accounted for a part ...
... , FRIDAY, March 30 (HealthDay News) -- The health ... be greater in girls than in boys, a new study ... and found that those who were exposed to high levels ... 2 were at higher risk for decreased lung function at ...
... Reporter , FRIDAY, March 30 (HealthDay News) -- Now comes ... ended Wednesday over the constitutionality of the health-reform legislation passed ... Supreme Court will meet Friday and begin to decide whether ... While their final decision won,t be announced until June, ...
Cached Medicine News:Health News:Diabetes Drug Metformin Might Also Help Fight Cancer 2Health News:Diabetes Drug Metformin Might Also Help Fight Cancer 3Health News:Diabetes Drug Metformin Might Also Help Fight Cancer 4Health News:FDA Calls on Tobacco Companies to List Harmful Ingredients 2Health News:Metformin appeared to slow prostate cancer growth 2Health News:U.S. Women in Labor Longer Than They Were 50 Years Ago 2Health News:Secondhand Smoke Affects Young Girls More Than Boys: Study 2Health News:Justices Meet to Decide Fate of Health-Reform Legislation 2Health News:Justices Meet to Decide Fate of Health-Reform Legislation 3Health News:Justices Meet to Decide Fate of Health-Reform Legislation 4Health News:Justices Meet to Decide Fate of Health-Reform Legislation 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: